SCI Pharmtech, Inc. (TPE: 4119)

Market Cap	10.13B
Revenue (ttm)	1.41B
Net Income (ttm)	484.24M
Shares Out	119.51M
EPS (ttm)	4.08
PE Ratio	20.78
Forward PE	n/a
Dividend	1.25 (1.48%)
Ex-Dividend Date	n/a

Volume	98,181
Average Volume	186,003
Open	84.20
Previous Close	84.20
Day's Range	83.80 - 84.90
52-Week Range	82.50 - 98.50
Beta	-0.24
RSI	27.86
Earnings Date	Mar 18, 2025

About SCI Pharmtech

SCI Pharmtech, Inc., together with its subsidiary, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals in Italy, the United States, Japan, Germany, Taiwan, Switzerland, China, and internationally. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychloroquine sulfate, loxoprofe...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Employees: 239
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 4119

Financial Performance

In 2023, SCI Pharmtech's revenue was 1.20 billion, an increase of 33.83% compared to the previous year's 899.74 million. Earnings were 294.72 million, a decrease of -4.55%.